AG 041R

Drug Profile

AG 041R

Latest Information Update: 18 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antiulcers
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoarthritis; Peptic ulcer

Most Recent Events

  • 18 Jul 2006 No development reported - Preclinical for Osteoarthritis in Japan (unspecified route)
  • 10 Apr 2003 Preclinical trials in Osteoarthritis in Japan (unspecified route)
  • 10 Apr 2003 Two preclinical studies have been added to the Rheumatic Disease pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top